Clinical Research Directory

Inclusion Criteria: * 16 years of age or older, male or female * Life expectancy of at least 3 months * Confirmed tumor by imaging studies * Have adequate organ function, as measured by laboratory values: Lymphocyte ratio \>20%; WBC \>3.0×10\^9/L; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN; if the patient has liver metastases, ALT and AST ≤5 × ULN; Alkaline phosphatase (ALP）≤2.5 × ULN; total serum bilirubin (TBIL) \< 1.5 × ULN; Urea nitrogen (BUN）≤1.5 × ULN; Creatinine (Cr）1.5≤ULN; Normal blood coagulation function, urine routine, and electrocardiogram (ECG) * Available tumor specimen for sequencing and neoantigen determination * Ability to find 3 or more neoantigen epitopes * Ability to follow research and follow-up procedures * Able to understand and willing to sign an IRB approved written informed consent document * Agree with the use of contraception or partner of child-bearing potential agrees to use adequate contraception which will include two of the following: hormonal or barrier method of birth control, or abstinence prior to study entry, for the duration of study participation, and for 30 days following completion of therapy Exclusion Criteria: * History of immunodeficiency disorder or autoimmune condition requiring active immunosuppressive therapy * Evidence of Liver and kidney dysfunction, severe heart disease, or coagulation dysfunction * Known diagnosis of an infectious condition including hepatitis, HIV, CMV, and Treponema pallidum * Participant becomes pregnant and/or is breastfeeding or plans on becoming pregnant during study * A psychiatric illness that would limit compliance with study requirements as determined by the investigator or the investigator believes that participant is not suitable for inclusion